If you have been reading about peptide degradation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
== Pharmacokinetics == After intravenous administration in humans, methylene blue shows a multiphasic change in concentration, with a terminal half-life of 5.25 hours. The initial disappearance from blood actually reflects its movement into organs, with brain, liver, and bile all showing significantly higher concentrations than blood in rats. The overall area under the curve in oral (dry gelatin capsule) administration is only 6.5% of the AUC for IV administration; judging from rat studies, the significantly altered organ distribution plays a key role in this difference. Administration as an oral solution (500 mg in 200 mL) greatly increases the bioavailability to 72.3±23.9%. In this newer study, the terminal half-lives were reported as 18.5±11.8 hours for IV use and 18.3±7.2 hours for oral use. The tmax for oral use is 2.2 hours, compared to 0.5 hours for iv use.
(ASAXAA/ ASAp)(Ttc) where ASAp refers to the area of the entire fused protein that is available to the solvent that is being used, ASAXAA refers to the area of the guest residue on the ELP that is available to the solvent, and Ttc is the transition temperature that is unique to the amino acid. Summing up the contribution of each potential guest residue (XAA) will yield an SI index that is directly proportional to ΔTt,fusion. It was found that the amino acids that are charged under a physiological pH of 7.4 have the greatest impact on the overall SI of a fused protein. This is due to the fact that they are more accessible to water-containing solvents, thereby increasing the ASAXAA and also have high Ttc values. Hence, knowledge of the transition temperature of a fused protein is highly dependent on the presence of these charged residues.
Convergent evolution—the repeated evolution of similar traits in multiple lineages which all ancestrally lack the trait—is rife in nature, as illustrated by the examples below. The ultimate cause of convergence is usually a similar evolutionary biome, as similar environments will select for similar traits in any species occupying the same ecological niche, even if those species are only distantly related. In the case of cryptic species, it can create species which are only distinguishable by analysing their genetics. Distantly related organisms often develop analogous structures by adapting to similar environments.
Masa or masa de maíz (English: ; Spanish pronunciation: [ˈmasa]) is a dough made from ground nixtamalized corn. It is used for making corn tortillas, gorditas, tamales, pupusas, and many other Latin American dishes. It is dried and powdered into a flour form called harina de maíz or masa harina. Masa is reconstituted by mixing with water before using it in cooking. In Spanish, masa translates simply to "dough" and harina translates to "flour", but the name masa harina does not follow Spanish grammar and the term does not exist in Spanish.
Sources: en.wikipedia.org
== Etiology == Inoculation of throat washings taken from people with this disease into the brains of newborn mice revealed that enteroviruses in the Coxsackie B virus group were likely to be the cause of pleurodynia, and those findings were supported by subsequent studies of IgM antibody responses measured in serum from people with pleurodynia. Other viruses in the enterovirus family, including echovirus and Coxsackie A virus, are less frequently associated with pleurodynia. Echovirus types 1,6,8,9, and 19 and Coxsackie A virus types 4,6,9, and 10 are associated with Bornholm disease. The most common strains causing Bornholm disease are Coxsackie B3 and A9. Viral proliferation in the muscles of the chest wall, diaphragm, and abdomen are thought to contribute to the typical presentation that characterizes the illness.
As a second lieutenant in 1966, Noriega spent many months taking courses at the School of the Americas. The school was located at the United States Army's Fort Gulick in the Panama Canal Zone. Journalist John Dinges has suggested that Torrijos sent Noriega to the school to help him "shape up" and live up to Torrijos's expectations. Despite performing poorly in his classes, he was promoted to the rank of first lieutenant in 1966, and Torrijos found him a job as an intelligence officer in the "North Zone" of the National Guard. Shortly afterward, he returned to the School of the Americas for more training. At the school, Noriega participated in courses on infantry operations, counterintelligence, intelligence, and jungle warfare. He also took a course in psychological operations at Fort Bragg in North Carolina. Noriega's job required him to penetrate and disrupt the trade unions that had formed in the United Fruit Company's workforce, and he proved adept at this work. His new superior officer Boris Martínez was a fervent anti-communist, and enforced strict discipline on Noriega. Reports have suggested that he continued to pass intelligence to the U.S. during this period, about the plantation workers' activities. In 1967 the administration of U.S. President Lyndon B. Johnson concluded that Noriega would be a valuable asset, as he was a "rising star" in the Panamanian military. Later, as the de facto leader of Panama, Noriega maintained a close relationship with the School of the Americas, partly due to the school's presence in Panama.
== Causes == Mutations in the COL2A1 gene can cause a number of skeletal abnormalities, including achondrogenesis type 2. Instructions for producing a protein that produces type II collagen are provided by this gene. Type II collagen molecule assembly is disrupted by mutations in the COL2A1 gene, impairing the normal development of bones and other connective tissues. Because achromogenesis type 2 is caused by a mutated gene that only needs one copy in each cell, it is regarded as an autosomal dominant disorder.
On 5 June, the IDF said that it struck underground facilities in Dahieh that were used by Hezbollah's Unit 127 to produce thousands of drones with funding from Iran. The strikes marked the largest escalation of the conflict since the ceasefire. On 24 October, two people were killed and two others were injured in an Israeli airstrike on a vehicle in Toul, Lebanon. The IDF said that it struck the head of logistics in Hezbollah's Southern Front Abbas Hassan Karaki whose presence in the south of Lebanon violated the ceasefire terms. On 18 November, an Israeli strike hit a parked car at the Ain al-Hilweh Palestinian refugee camp, killing 13 people. The IDF said it hit a Hamas training camp. On 23 November, an Israeli strike in Haret Hreik killed five people and injured 28 others. Haytham Ali Tabatabai, Hezbollah's chief of staff and second-in-command, was killed in the attack. On the one-year anniversary of the ceasefire, The New York Times characterized the conflict as still ongoing with "near-daily" attacks by Israel into Lebanon. On 20 February 2026, Israeli airstrikes in the Baalbek area killed ten people, including eight Hezbollah members, and injured 24 others. Three of the dead were identified as local Hezbollah commanders. A separate strike that day in Ain al-Hilweh killed two people, which the IDF said hit a Hamas command center. On 21 February, Arab media reported that IRGC officers took responsibility for supervising Hezbollah's activities, increasing its military preparedness in anticipation of an Israeli or American attack amid the Iran–United States crisis.
Wheeler was awarded the Lab on a Chip Pioneers in Miniaturization Award (2017), an E.W.R. Steacie Fellowship from the Natural Sciences and Engineering Research Council of Canada (NSERC) (2015), a Connaught Foundation McLean Fellowship (2014), the Joseph Black Award from the Royal Society of Chemistry (2012), the Arthur F. Findeis Award from the American Chemical Society (2012), the Young Innovator Award in Analytical Chemistry (2011), and a Sloan Research Fellowship (2009). In January 2024, Wheeler was honored with the Ricardo Aroca Award, recognizing his contributions to analytical chemistry and advancing lab-on-a-chip techniques, particularly through the use of digital microfluidics (DMF), which enables precise manipulation of liquid droplets on electrode arrays. The Award is bestowed upon a scientist living in Canada who has made a notable contribution to the discipline of analytical chemistry while conducting research within the country.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.